lomustine has been researched along with Thrombocytopenia in 41 studies
Thrombocytopenia: A subnormal level of BLOOD PLATELETS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we explored the incidence, and the consequences for treatment exposure and survival, of thrombocytopenia induced by lomustine in recurrent glioblastoma." | 9.69 | Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. ( Brandes, AA; Clement, PM; Golfinopoulos, V; Gorlia, T; Idbaih, A; Le Rhun, E; Oppong, FB; Platten, M; Preusser, M; Taphoorn, MJ; van den Bent, M; Weller, M; Wick, W, 2023) |
| "Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain." | 9.12 | A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007) |
| "A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas." | 9.08 | Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 9.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0." | 9.05 | Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982) |
| "Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B)." | 9.05 | Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S, 1985) |
| "Twelve previously untreated patients with histologically documented, metastatic, malignant melanoma were treated with the combination of procarbazine, vincristine, CCNU, and cyclophosphamide, with an objective response rate of 33%." | 7.66 | Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma. ( Dillman, RO; Green, MR; Horton, C, 1980) |
| " Here, we explored the incidence, and the consequences for treatment exposure and survival, of thrombocytopenia induced by lomustine in recurrent glioblastoma." | 5.69 | Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. ( Brandes, AA; Clement, PM; Golfinopoulos, V; Gorlia, T; Idbaih, A; Le Rhun, E; Oppong, FB; Platten, M; Preusser, M; Taphoorn, MJ; van den Bent, M; Weller, M; Wick, W, 2023) |
| " All patients required dosage modification for toxicity." | 5.28 | Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. ( Evans, AE; Lefkowitz, IB; Packer, RJ; Schut, L; Siegel, KR; Sutton, LN, 1990) |
| "Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain." | 5.12 | A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007) |
| "A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas." | 5.08 | Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 5.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0." | 5.05 | Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982) |
| "Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B)." | 5.05 | Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S, 1985) |
| "Nineteen patients with advanced non-Hodgkin's lymphoma resistant to previous chemotherapy were treated with combination chemotherapy consisting of lomustine (CCNU), cytarabine, and prednisone." | 3.66 | Salvage chemotherapy for non-Hodgkin's lymphoma. ( Khoo, RK; Ng, PR; Todd, D, 1982) |
| "Twelve previously untreated patients with histologically documented, metastatic, malignant melanoma were treated with the combination of procarbazine, vincristine, CCNU, and cyclophosphamide, with an objective response rate of 33%." | 3.66 | Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma. ( Dillman, RO; Green, MR; Horton, C, 1980) |
| "To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU." | 2.74 | High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. ( Deckert, M; Feuerhake, F; Finke, J; Ihorst, G; Illerhaus, G; Marks, R; Müller, F; Ostertag, C, 2009) |
| "Lomustine is a commercially available chloroethyl nitrosourea compound whose antitumor activity in vitro and in animal tumor models exceeds its activity in humans." | 2.67 | A phase I trial of weekly lomustine in patients with advanced cancer. ( Benjamin, RS; Gorski, CC; Koller, CA; Legha, SS; Papadopoulos, NE; Plager, C, 1994) |
| "Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD)." | 2.65 | Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine. ( Bond, WH; Chenoweth, L; Einhorn, LH; Stevens, EE; Williams, SD, 1983) |
| "Thirty-five patients with advanced breast cancer refractory to initial chemotherapy were randomized to receive two-drug doxorubicin-CCNU or three-drug doxorubicin-CCNU-vincristine (VCR) treatment." | 2.65 | Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trial. ( Bateman, JR; Block, JB; Chlebowski, RT; Pugh, R; Weiner, JM, 1983) |
| " The dosage of CCNU was 100 mg/m2 p." | 2.65 | The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. ( Brunner, K; Cuttner, J; Falkson, G; Hansen, HH; Holland, JF; Nissen, NI; Pajak, TF; Selawry, OS; Spurr, CL, 1981) |
| "It is an effective drug in the treatment of malignant melanoma with better response rates in women than in men." | 2.64 | Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. ( Hill, G; Johnson, RO; Krementz, E; Metter, G; Wilson, W, 1976) |
| "Thrombocytopenia was the primary toxic reaction." | 2.64 | A clinical trial of CCNU (1-(2 chloroethyl)-3-cyclohexyl-1-nitrosourea) (NSC 79037) in advanced ovarian carcinoma. ( Fletcher, WS; McConnell, DB; Merhoff, GC; Moseley, HS; Sasaki, TM, 1975) |
| " All patients required dosage modification for toxicity." | 1.28 | Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. ( Evans, AE; Lefkowitz, IB; Packer, RJ; Schut, L; Siegel, KR; Sutton, LN, 1990) |
| "One patient with Hodgkin's disease involving the liver is alive at 36 months with further therapy." | 1.26 | Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease. ( Gamble, JF; Loh, KK; Rodgers, RW; Shullenberger, CC, 1980) |
| " The treatment dosage was 130 mg/m2 for patients with adequate bone marrow reserve and 100 mg/m2 for those with compromised bone marrow." | 1.26 | Treatment of advanced malignancy with CCNU (NSC 79037): a phase II cooperative study with long-term follow up. ( Armstrong, DM; Aust, JB; Cruz, AB; Fletcher, WS; Metter, G; Richardson, JD; Wilson, WL, 1976) |
| " In the first phase, 14 patients (Group A) with progressive neurologic dysfunction following primary treatment were treated with DTIC alone (8 patients) or in combination with CCNU or methyl CCNU (6 patients) and evaluated for change in neurologic status." | 1.25 | Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441). ( Baxter, D; Cunningham, TJ; Horton, J; Nelson, L; Olson, KB; Rosenbaum, C; Sponzo, RW; Taylor, SG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (68.29) | 18.7374 |
| 1990's | 5 (12.20) | 18.2507 |
| 2000's | 4 (9.76) | 29.6817 |
| 2010's | 2 (4.88) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| Authors | Studies |
|---|---|
| Le Rhun, E | 3 |
| Oppong, FB | 3 |
| van den Bent, M | 3 |
| Wick, W | 3 |
| Brandes, AA | 3 |
| Taphoorn, MJ | 3 |
| Platten, M | 3 |
| Idbaih, A | 3 |
| Clement, PM | 3 |
| Preusser, M | 3 |
| Golfinopoulos, V | 3 |
| Gorlia, T | 3 |
| Weller, M | 4 |
| Soileau, AM | 1 |
| Neto, RLALT | 1 |
| Jimenez, PT | 1 |
| Hamersky, J | 1 |
| Smith, AA | 1 |
| Illerhaus, G | 1 |
| Marks, R | 1 |
| Müller, F | 1 |
| Ihorst, G | 1 |
| Feuerhake, F | 1 |
| Deckert, M | 1 |
| Ostertag, C | 1 |
| Finke, J | 1 |
| Heading, KL | 1 |
| Brockley, LK | 1 |
| Bennett, PF | 1 |
| Abrams-Ogg, AC | 1 |
| Zander, T | 1 |
| Nettekoven, W | 1 |
| Kraus, JA | 1 |
| Pels, H | 1 |
| Ko, YD | 1 |
| Vetter, H | 1 |
| Klockgether, T | 1 |
| Schlegel, U | 1 |
| Larkin, JM | 1 |
| Hughes, SA | 1 |
| Beirne, DA | 1 |
| Patel, PM | 1 |
| Gibbens, IM | 1 |
| Bate, SC | 1 |
| Thomas, K | 1 |
| Eisen, TG | 1 |
| Gore, ME | 1 |
| Seigler, HF | 1 |
| Lucas, VS | 1 |
| Pickett, NJ | 1 |
| Huang, AT | 1 |
| Rodgers, RW | 1 |
| Gamble, JF | 1 |
| Loh, KK | 1 |
| Shullenberger, CC | 1 |
| Mead, GM | 1 |
| Harker, WG | 1 |
| Kushlan, P | 1 |
| Rosenberg, SA | 1 |
| Einhorn, LH | 1 |
| Williams, SD | 1 |
| Stevens, EE | 1 |
| Bond, WH | 1 |
| Chenoweth, L | 1 |
| Robustelli della Cuna, G | 1 |
| Paoletti, P | 1 |
| Bernardo, G | 1 |
| Knerich, R | 1 |
| Butti, G | 1 |
| Cuzzoni, Q | 1 |
| Wilson, HE | 1 |
| Stanley, K | 1 |
| Vincent, RG | 1 |
| Mountain, CF | 1 |
| Sealy, R | 2 |
| Cohen, M | 1 |
| Chen, TY | 1 |
| Batley, F | 1 |
| Kilman, J | 1 |
| Kakos, G | 1 |
| Vasko, J | 1 |
| Williams, TE | 1 |
| Tucker, RD | 2 |
| Chlebowski, RT | 1 |
| Pugh, R | 1 |
| Weiner, JM | 1 |
| Block, JB | 1 |
| Bateman, JR | 2 |
| Chahinian, AP | 2 |
| Green, G | 1 |
| Holland, JF | 4 |
| Hansen, HH | 4 |
| Dombernowsky, P | 2 |
| Hirsch, FR | 1 |
| Hansen, M | 2 |
| Rygård, J | 1 |
| Selawry, OS | 2 |
| Pajak, TF | 3 |
| Spurr, CL | 1 |
| Falkson, G | 1 |
| Brunner, K | 2 |
| Cuttner, J | 2 |
| Nissen, NI | 2 |
| Cornwell, GG | 1 |
| Kochwa, S | 1 |
| McIntyre, OR | 1 |
| Glowienka, LP | 1 |
| Rafla, S | 1 |
| Silver, RT | 2 |
| Cooper, MR | 1 |
| Henderson, E | 1 |
| Kyle, RA | 1 |
| Haurani, FI | 1 |
| Ng, PR | 1 |
| Todd, D | 1 |
| Khoo, RK | 1 |
| Gagliano, RG | 1 |
| Panettiere, FJ | 1 |
| Haas, CD | 1 |
| Baker, L | 1 |
| Hewlett, J | 1 |
| Stuckey, WJ | 1 |
| O'Bryan, RM | 1 |
| Bottomley, R | 1 |
| Heilburn, LK | 1 |
| Green, MR | 1 |
| Dillman, RO | 1 |
| Horton, C | 1 |
| Samuel, LM | 1 |
| Harvey, VJ | 1 |
| Mitchell, PL | 1 |
| Thompson, PI | 1 |
| Mak, D | 1 |
| Melville, P | 1 |
| Evans, BD | 1 |
| Koller, CA | 1 |
| Gorski, CC | 1 |
| Benjamin, RS | 1 |
| Legha, SS | 1 |
| Papadopoulos, NE | 1 |
| Plager, C | 1 |
| Chamberlain, MC | 1 |
| Kormanik, PA | 1 |
| Abele, M | 1 |
| Leonhardt, M | 1 |
| Dichgans, J | 1 |
| Colombi, M | 1 |
| Guffanti, A | 1 |
| Alietti, A | 1 |
| Latargia, ML | 1 |
| Vener, C | 1 |
| Maiolo, AT | 1 |
| Baldini, L | 1 |
| Zeltzer, PM | 1 |
| Feig, SA | 1 |
| Taylor, SG | 1 |
| Nelson, L | 1 |
| Baxter, D | 1 |
| Rosenbaum, C | 1 |
| Sponzo, RW | 1 |
| Cunningham, TJ | 1 |
| Olson, KB | 1 |
| Horton, J | 1 |
| Stolinsky, DC | 1 |
| Bull, FE | 1 |
| Simon, R | 2 |
| Carr, DT | 1 |
| van Wyk, CE | 1 |
| Mandel, EM | 1 |
| Jaffrey, IS | 1 |
| Teirstein, AS | 1 |
| Maurice, P | 1 |
| Glidewell, O | 1 |
| Jacquillat, C | 1 |
| Carey, R | 1 |
| Pas, AT | 1 |
| Cornell, CJ | 1 |
| Burningham, RA | 1 |
| Alberto, P | 1 |
| Barrelet, L | 1 |
| Chapuis, B | 1 |
| Garcia, B | 1 |
| Johnson, RO | 1 |
| Metter, G | 2 |
| Wilson, W | 1 |
| Hill, G | 1 |
| Krementz, E | 1 |
| Tejada, F | 1 |
| Eisenberger, MA | 1 |
| Broder, LA | 1 |
| Cohen, MH | 1 |
| Cruz, AB | 1 |
| Armstrong, DM | 1 |
| Aust, JB | 1 |
| Fletcher, WS | 2 |
| Wilson, WL | 1 |
| Richardson, JD | 1 |
| Sasaki, TM | 1 |
| McConnell, DB | 1 |
| Moseley, HS | 1 |
| Merhoff, GC | 1 |
| Lefkowitz, IB | 1 |
| Packer, RJ | 1 |
| Siegel, KR | 1 |
| Sutton, LN | 1 |
| Schut, L | 1 |
| Evans, AE | 1 |
| Osterlind, K | 1 |
| Hansen, HS | 1 |
| Rørth, M | 1 |
| Lahouel, M | 1 |
| Viotte, G | 1 |
| Sumereau, E | 1 |
| Morin, JP | 1 |
| Fillastre, JP | 1 |
| Bajetta, E | 1 |
| Buzzoni, R | 1 |
| Viviani, S | 1 |
| Vaglini, M | 1 |
| Nava, M | 1 |
| Bonadonna, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy[NCT00989352] | Phase 2 | 56 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 trials available for lomustine and Thrombocytopenia
| Article | Year |
|---|---|
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Comb | 2009 |
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarb | 2007 |
Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine.
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 1983 |
Comparison of chemotherapy alone versus chemotherapy and radiation therapy of extensive small cell carcinoma of the lung.
Topics: Aged; Body Weight; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, | 1983 |
Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trial.
Topics: Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Female; Humans; | 1983 |
Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1984 |
Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Bronchogenic; Clinical Trials as Top | 1980 |
The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study.
Topics: Adult; Carmustine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration S | 1981 |
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
Topics: Antineoplastic Agents; Carmustine; Drug Administration Schedule; Drug Therapy, Combination; Female; | 1982 |
Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lomustine; Male; Melano | 1994 |
A phase I trial of weekly lomustine in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Capsules; Carcinoma, Renal Cell; Drug Administration Schedule; Dr | 1994 |
Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
Topics: Adult; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; | 1997 |
OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma.
Topics: Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cau | 2000 |
Combination chemotherapy of advanced lung cancer: a randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; | 1976 |
Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma.
Topics: Clinical Trials as Topic; Female; Hodgkin Disease; Humans; Leukopenia; Lomustine; Lymphoma, Non-Hodg | 1978 |
A combination of adriamycin, CCNU and hydroxyurea in the treatment of disseminated bronchogenic carcinoma.
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug Thera | 1975 |
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Femal | 1976 |
5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer.
Topics: Drug Evaluation; Fluorouracil; Humans; Leukopenia; Lomustine; Male; Neoplasm Metastasis; Nitrosourea | 1977 |
A clinical trial of CCNU (1-(2 chloroethyl)-3-cyclohexyl-1-nitrosourea) (NSC 79037) in advanced ovarian carcinoma.
Topics: Alkylating Agents; Clinical Trials as Topic; Female; Humans; Lomustine; Nitrosourea Compounds; Ovari | 1975 |
Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Com | 1986 |
Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic | 1985 |
19 other studies available for lomustine and Thrombocytopenia
| Article | Year |
|---|---|
Doxorubicin and zoledronate treatment in a dog with hemophagocytic histiocytic sarcoma.
Topics: Animals; Dog Diseases; Dogs; Doxorubicin; Histiocytic Sarcoma; Hyperbilirubinemia; Hypoalbuminemia; | 2023 |
CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
Topics: Anemia; Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Female; Gastrointestinal Dis | 2011 |
The use of lithium carbonate to prevent lomustine-induced myelosuppression in dogs: a pilot study.
Topics: Animals; Antidepressive Agents; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Dose-Response | 2011 |
Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Female | 2002 |
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Drug Administration Schedule; Drug Evaluation; Drug Th | 1980 |
Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Dacarbazine; Doxorubicin; Drug Administra | 1980 |
Single agent palliative chemotherapy for end-stage Hodgkin's disease.
Topics: Adolescent; Adult; Female; Hodgkin Disease; Humans; Lomustine; Male; Middle Aged; Nitrosourea Compou | 1982 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
Salvage chemotherapy for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukopenia; Lomustine; Lymphoma; | 1982 |
Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Colonic Neoplasms; Deoxyguanosine; Drug Evaluation; Drug Therapy, Combination; Human | 1981 |
Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lomustine; | 1980 |
CCNU overdose during PCV chemotherapy for anaplastic astrocytoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neo | 1998 |
Theophylline-induced lomustine toxicity.
Topics: Drug Synergism; Female; Humans; Leukopenia; Lomustine; Middle Aged; Nitrosourea Compounds; Theophyll | 1979 |
Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441).
Topics: Adult; Brain Neoplasms; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Glioblastom | 1975 |
Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma 1,2,3.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma, Bronchogenic; Carcinoma, Small Cell; | 1975 |
MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; | 1979 |
Treatment of advanced malignancy with CCNU (NSC 79037): a phase II cooperative study with long-term follow up.
Topics: Humans; Leukopenia; Lomustine; Neoplasms; Nitrosourea Compounds; Thrombocytopenia | 1976 |
Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Child; Child, Pres | 1990 |
Haematotoxicity of doxorubicin and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and of their association in rats.
Topics: Animals; Blood Cell Count; Body Weight; Creatinine; Doxorubicin; Female; Hemoglobins; Leukopenia; Lo | 1987 |